Gubra

CompanyDenmark

Gubra develops one asset, preclinical (GUB-UCN2 in obesity). Mostly peptide acting on lipid and ceramide metabolism and CRHR2; based in Denmark.

1
Asset
Furthest stage: Preclinical; 0
Trials: 1
Signal

Pipeline

1

GUB-UCN2
Long-acting UCN2 analogue selectively activates CRHR2 to increase muscle mass, reduce fat mass, and improve glucose metabolism.
Preclinical, Peptide, Lipid and ceramide metabolism, CRHR2, obesity

Full company profiles: pipeline, trials, funding and people.

In the full profile

Evidence behind the mechanisms3
Signals2
Similar companies6

Papers

GUB-UCN2 as Monotherapy and in Combination with Semaglutide Increases Muscle Mass, Reduces Fat Mass, and Improves Metabolic Outcomes in Aged Diet-Induced Obese Rats
ADA Scientific Sessions 2026 abstract, 5 Jun 2026
Dietary intervention reverses molecular markers of hepatocellular senescence in the GAN diet-induced obese and biopsy-confirmed mouse model of NASH
BMC gastroenterology, 3 Feb 2024